Header Logo

ELENI EFSTATHIOU

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
Address1155 Pressler St
Houston TX 77030-3721
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, Suzuki H, Taplin ME, Thellenberg-Karlsson C, Tilki D, T?rkeri LN, Uemura H, ?r?n Y, Vale CL, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). Eur Urol. 2024 Oct 10. PMID: 39394013.
      Citations: 1     Fields:    
    2. Rathkopf DE, Roubaud G, Chi KN, Efstathiou E, Attard G, Olmos D, Small EJ, Saad M, Castro E, Kim W, Wu D, Bertzos K, Dibaj S, Zhang J, Francis P, Smith MR. Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. Eur Urol. 2024 Sep 23. PMID: 39317633.
      Citations:    Fields:    
    3. Ranganathan S, Riveros C, Xu J, Hu S, Geng M, Huang E, Melchiode Z, Zhang J, Efstathiou E, Chan KS, Wallis CJD, Sonpavde G, Satkunasivam R. Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience. Urol Oncol. 2024 Sep; 42(9):291.e13-291.e25. PMID: 38763801.
      Citations:    Fields:    Translation:Humans
    4. Efstathiou E, Merseburger A, Liew A, Kurtyka K, Panda O, Dalechek D, Heerdegen ACS, Jain R, De Solda F, McCarthy SA, Brookman-May SD, Mundle SD, Yu Ko W, Krabbe LM. Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents. ESMO Open. 2024 May; 9(5):103007. PMID: 38744101; PMCID: PMC11108859.
      Citations:    Translation:Humans
    5. Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun. 2023 12 13; 3(12):2531-2543. PMID: 37930121; PMCID: PMC10718063.
      Citations:    Translation:HumansAnimalsCells
    6. Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, Giorgi U, Shore ND, Saad F. Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? Future Oncol. 2023 Sep; 19(29):1953-1960. PMID: 37585665.
      Citations:    Fields:    
    7. Agarwal N, Zhang T, Efstathiou E, Sayegh N, Engelsberg A, Saad F, Fizazi K. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer. 2023 10; 192:113249. PMID: 37672815.
      Citations: 1     Fields:    Translation:Humans
    8. Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, Castro E, Roubaud G, Pereira de Santana Gomes AJ, Small EJ, Rathkopf DE, Gurney H, Jung W, Mason GE, Dibaj S, Wu D, Diorio B, Urtishak K, Del Corral A, Francis P, Kim W, Efstathiou E. Niraparib plus abiraterone acetate with prednisone in patients with?metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the?randomized phase III MAGNITUDE trial. Ann Oncol. 2023 09; 34(9):772-782. PMID: 37399894; PMCID: PMC10849465.
      Citations:    
    9. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 06 01; 9(6):825-834. PMID: 37022702; PMCID: PMC10080407.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    10. Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S, MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 06 20; 41(18):3339-3351. PMID: 36952634; PMCID: PMC10431499.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    11. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, T?rkeri L, Turco F, Uemura H, Uemura H, ?r?n Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. PMID: 37003085.
      Citations: 3     Fields:    Translation:Humans
    12. Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, De Giorgi U, Shore ND, Saad F. Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. J Urol. 2023 03; 209(3):532-539. PMID: 36756959.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    13. Riveros C, Ranganathan S, Xu J, Chang C, Kaushik D, Morgan M, Miles BJ, Muhammad T, Anis M, Aghazadeh M, Zhang J, Efstathiou E, Klaassen Z, Brooks MA, Rini B, Wallis CJD, Satkunasivam R. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy. Urol Oncol. 2023 03; 41(3):150.e1-150.e9. PMID: 36610815.
      Citations: 2     Fields:    Translation:Humans
    14. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, T?rkeri L, Turco F, Uemura H, Uemura H, ?r?n Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A, Jereczek-Fossa BA. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. PMID: 36494221; PMCID: PMC7614721.
      Citations: 7     Fields:    Translation:Humans
    15. De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 2022 Nov; 18(35):3867-3874. PMID: 36226865.
      Citations:    Fields:    
    16. Wallis CJ, Satkunasivam R, Lim K, Teh BS, Guzman J, Zhang J, Farach A, Chen SH, Efstathiou E, Esnaola NF, Sonpavde GP. A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial. Future Oncol. 2022 Aug; 18(25):2771-2781. PMID: 35703113.
      Citations:    Fields:    Translation:Humans
    17. Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol. 2022 11; 40(11):1624-1633. PMID: 35697807; PMCID: PMC9646498.
      Citations:    Fields:    
    18. Dursun F, Lim K, Svatek RS, Xu J, El-Zaatari ZM, Wenker EP, Klaassen ZW, Mansour AM, Muhammad T, Efstathiou E, Sonpavde GP, Wallis CJD, Satkunasivam R. Clinical outcomes and patterns of population-based management of urachal carcinoma of the bladder: An analysis of the National Cancer Database. Cancer Med. 2022 11; 11(22):4273-4282. PMID: 35509235; PMCID: PMC9678087.
      Citations:    Fields:    
    19. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A, Bjartell A, Heinrich D, Maluf F, Saad F, T?rkeri L. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):115-141. PMID: 35450732.
      Citations:    Fields:    Translation:Humans
    20. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A, Bjartell A, Fanti S, Heinrich D, Maluf F, Saad F, T?rkeri L. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82(1):e18-e19. PMID: 35440417; PMCID: PMC9012951.
      Citations:    Fields:    
    21. Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, Chakraborty G, Wang X, Chen H, Jiang Y, Kumar D, Caggiano EG, Capogiri M, Zhang B, Ji Y, Maity SN, Hu M, Bai S, Aparicio AM, Efstathiou E, Logothetis CJ, Navin N, Navone NM, Chen Y, Giancotti FG. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022 04 05; 39(1):110595. PMID: 35385726; PMCID: PMC9414743.
      Citations:    Fields:    Translation:HumansAnimalsCells
    22. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797. PMID: 35379845; PMCID: PMC8980015.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    23. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A, Bjartell A, Fanti S, Heinrich D, Maluf F, Saad F, T?rkeri L. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11. PMID: 35393158; PMCID: PMC8849852.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    24. Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, GALAHAD investigators, Saad F, St?hl O, Olmos D. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022 03; 23(3):362-373. PMID: 35131040; PMCID: PMC9361481.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    25. Celtik K, Lim K, Dursun F, Xu J, Klaassen Z, Zhang J, Efstathiou E, Sonpavde G, Wallis C, Satkunasivam R. Association Between Perioperative Chemotherapy and Survival in Men Undergoing Radical Resection for Primary Urethral Urothelial Carcinoma: An Analysis of the National Cancer Database. Clin Genitourin Cancer. 2022 06; 20(3):244-251. PMID: 35181268.
      Citations: 1     Fields:    Translation:Humans
    26. Vogl UM, Beer TM, Davis ID, Shore ND, Sweeney CJ, Ost P, Attard G, Bossi A, de Bono J, Drake CG, Efstathiou E, Fizazi K, Halabi S, James N, Mottet N, Padhani AR, Roach M, Rubin M, Sartor O, Small E, Smith MR, Soule H, Sydes MR, Tombal B, Omlin A, APCCC 2019 expert panel, Fanti S, Gillessen S. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer. 2022 01; 160:24-60. PMID: 34844839.
      Citations:    Fields:    Translation:Humans
    27. De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN, Saad F. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. Eur J Cancer. 2021 12; 159:237-246. PMID: 34784577.
      Citations: 2     Fields:    Translation:Humans
    28. Efstathiou E, Attard G, Flaig TW, Goodman OB, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE, ACIS Investigators, Saad F, Franke F, Oudard S. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021 11; 22(11):1541-1559. PMID: 34600602; PMCID: PMC9377412.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    29. Labanca E, Anselmino N, Yang J, Shepherd PDA, Hoang AG, Tang X, Raso MG, Titus M, Efstathiou E, Araujo J, Logothetis C, Navone N, Bizzotto J, Sanchis P, Paez A, Antico-Arciuch V, Lage-Vickers S, Cotignola J, Vazquez E, Gueron G. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene. 2021 11; 40(44):6284-6298. PMID: 34584218; PMCID: PMC8566229.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    30. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-na?ve prostate cancer. Eur J Cancer. 2021 11; 157:259-267. PMID: 34536949.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    31. Grypari IM, Logotheti S, Zolota V, Troncoso P, Efstathiou E, Bravou V, Melachrinou M, Logothetis C, Tzelepi V. The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine (Baltimore). 2021 Sep 10; 100(36):e27094. PMID: 34516499; PMCID: PMC8428700.
      Citations: 2     Fields:    Translation:HumansCells
    32. Baiomy A, Martiniova L, Efstathiou E, Schuster DM, Ravizzini G. Prostate Cancer Liver Metastases Presenting as Relatively Photopenic Lesions on 18F-Fluciclovine PET/CT. Clin Nucl Med. 2021 Apr 01; 46(4):e240-e241. PMID: 33208612.
      Citations:    Fields:    Translation:Humans
    33. Wu WF, Wang L, Spetsieris N, Boukovala M, Efstathiou E, Warner M, Gustafsson JA, Br?ssner C. Estrogen receptor ? and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate. Proc Natl Acad Sci U S A. 2021 03 30; 118(13). PMID: 33771918; PMCID: PMC8020780.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    34. Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh N, Guerra L, Lee YC, Lin SC, Yu G, Santos E, Melancon MP, Troncoso P, Navone N, Gallick GE, Efstathiou E, Subudhi SK, Lin SH, Logothetis CJ, Panaretakis T. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264. PMID: 33753455; PMCID: PMC8172463.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    35. Spetsieris N, Boukovala M, Patsakis G, Alafis I, Efstathiou E. Neuroendocrine and Aggressive-Variant Prostate Cancer. Cancers (Basel). 2020 Dec 16; 12(12). PMID: 33339136; PMCID: PMC7765615.
      Citations: 8     
    36. Saad F, Sternberg CN, Efstathiou E, Fizazi K, Modelska K, Lin X, Sugg J, Steinberg J, Shore ND, Hussain M, Noerby B. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. Eur Urol. 2020 12; 78(6):847-853. PMID: 33010985.
      Citations:    Fields:    Translation:Humans
    37. Delanoy N, Hardy-Bessard AC, Efstathiou E, Moulec SL, Basso U, Birtle A, Thomson A, Krainer M, Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Gavrikova T, Sella A, Fizazi K, Ferrero JM, Thibault C, Hans S, Guillot A, Fl?chon A, Alexandre J, Helissey C, Thiery-Vuillemin A, Barth?l?my P, Laguerre B, Oudard S. Erratum to 'Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database' [European Journal of Cancer, Volume 125 (January 2020) Pages 153-163]. Eur J Cancer. 2020 Sep; 137:290-291. PMID: 32723589.
      Citations:    Fields:    
    38. Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Gavrikova T, Sella A, Fizazi K, Ferrero JM, Thibault C, Hans S, Guillot A, Fl?chon A, Alexandre J, Helissey C, Thiery-Vuillemin A, Barth?l?my P, Laguerre B, Oudard S. Corrigendum to "Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database" [Eur J Canc 125, (January 2020) 153-163]. Eur J Cancer. 2020 Sep; 137:288-289. PMID: 32605716.
      Citations:    Fields:    
    39. Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946. PMID: 32576626; PMCID: PMC7501166.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    40. Boukovala M, Spetsieris N, Efstathiou E. An evaluation of apalutamide for the treatment of prostate cancer. Expert Opin Pharmacother. 2020 Sep; 21(13):1537-1546. PMID: 32543237.
      Citations: 2     Fields:    Translation:HumansAnimals
    41. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5. PMID: 32675015; PMCID: PMC10014037.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    42. PROSPER Investigators, Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020 06 04; 382(23):2197-2206. PMID: 32469184.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    43. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, van Oort I, Zapatero A, Omlin A, Bjartell A, Fanti S, Heinrich D, Maluf F, Saad F, T?rkeri L. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. PMID: 32001144.
      Citations: 91     Fields:    Translation:Humans
    44. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75. PMID: 31986451; PMCID: PMC7350510.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    45. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999. PMID: 31941830.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    46. Tzelepi V, Logotheti S, Efstathiou E, Troncoso P, Aparicio A, Sakellakis M, Hoang A, Perimenis P, Melachrinou M, Logothetis C, Zolota V. Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology. 2020 Feb; 52(2):218-227. PMID: 31864524.
      Citations: 10     Fields:    Translation:HumansCells
    47. Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Gavrikova T, Sella A, Fizazi K, Ferrero JM, Thibault C, Hans S, Guillot A, Fl?chon A, Alexandre J, Helissey C, Thiery-Vuillemin A, Barth?l?my P, Laguerre B, Oudard S. Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database. Eur J Cancer. 2020 01; 125:153-163. PMID: 31787484.
      Citations: 2     Fields:    Translation:Humans
    48. Del Re M, Crucitta S, Sbrana A, Rofi E, Paolieri F, Gianfilippo G, Galli L, Falcone A, Morganti R, Porta C, Efstathiou E, van Schaik R, Jenster G, Danesi R, Efstathiou E, van Schaik R, Jenster G, Danesi R. Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer. BJU Int. 2019 Oct; 124(4):693-700. PMID: 31055861.
      Citations: 15     Fields:    
    49. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443. PMID: 31515154; PMCID: PMC6858999.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    50. Boukovala M, Spetsieris N, Efstathiou E. Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies. Drugs Aging. 2019 08; 36(8):701-717. PMID: 31172421.
      Citations: 5     Fields:    Translation:Humans
    51. Logothetis CJ, Aparicio A, Koinis F, Corn PG, Efstathiou E. Prostate Cancer: Quo Vadis? Eur Urol. 2019 Dec; 76(6):709-711. PMID: 31300238.
      Citations: 1     Fields:    Translation:Humans
    52. Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N, Oudard S, Payne H, Prentice M, Puts M, Aapro M, Droz JP. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer. 2019 07; 116:116-136. PMID: 31195356.
      Citations:    
    53. Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Troncoso P, Logothetis CJ. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. Eur Urol. 2019 10; 76(4):418-424. PMID: 31176622; PMCID: PMC7205516.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    54. Efstathiou E, Titus M, Wen S, Troncoso P, Hoang A, Corn P, Prokhorova I, Araujo J, Dmuchowski C, Melhem-Bertrandt A, Patil S, Logothetis CJ. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol. 2020 02; 3(1):119-127. PMID: 31412017; PMCID: PMC7204265.
      Citations: 8     Fields:    Translation:Humans
    55. Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clin Cancer Res. 2019 06 01; 25(11):3455-3467. PMID: 30808776; PMCID: PMC8211110.
      Citations: 9     Fields:    Translation:HumansCells
    56. Zacharias N, Lee J, Ramachandran S, Shanmugavelandy S, McHenry J, Dutta P, Millward S, Gammon S, Efstathiou E, Troncoso P, Frigo DE, Piwnica-Worms D, Logothetis CJ, Maity SN, Titus MA, Bhattacharya P. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol. 2019 02; 21(1):86-94. PMID: 29748904; PMCID: PMC6230314.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    57. Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E, Santer FR. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate. 2018 12; 78(16):1262-1282. PMID: 30073676.
      Citations: 33     Fields:    Translation:HumansAnimals
    58. Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Butt M, Priou F, Deville JL, Goupil MG, Morales R, Gavrikova T, Sella A, Fizazi K, Baciarello G, Fererro JM, Verret B, Hans S, Guillot A, Fl?chon A, Alexandre J, Helissey C, Lechevallier ?, Thiery-Vuillemin A, Barthelemy P, Laguerre B, Oudard S. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Eur Urol Oncol. 2018 12; 1(6):467-475. PMID: 31158090.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    59. Efstathiou E. The case for 'successfully' treating hormone na?ve metastatic prostate cancer. Ann Oncol. 2018 05 01; 29(5):1084-1086. PMID: 29688267.
      Citations:    Fields:    Translation:Humans
    60. Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, Gonzalez I, Castellano DE, Ozguroglu M, Carbonero IG, Balea BC, Esteban E, Rubio G, Birtle AJ, Delanoy N, Bellmunt J, Flechon A, Borrega P, Guillot A, Le Moulec S, Munarriz J, Oudard S. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents. Clin Genitourin Cancer. 2018 08; 16(4):e777-e784. PMID: 29550200.
      Citations: 6     Fields:    Translation:Humans
    61. Pezaro CJ, Omlin A, Mastris K, ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S, Saad F. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Ann Oncol. 2017 08 01; 28(8):1692-1694. PMID: 28838209.
      Citations: 2     Fields:    Translation:Humans
    62. Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Chi KN, Saad F. Prognostic Index Model for Progression-Free Survival in Chemotherapy-Na?ve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. Clin Genitourin Cancer. 2017 Jul 25. PMID: 28844792; PMCID: PMC5785489.
      Citations: 11     Fields:    
    63. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Drake CG, Eeles R, Efstathiou E, Evans CP, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Omlin A, Borges Dos Reis R, Fanti S, Heidenreich A, Maluf F, Saad F, Valdagni R, Wiegel T. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. PMID: 28655541.
      Citations: 162     Fields:    Translation:Humans
    64. Efstathiou E. Attaining precision therapy in prostate cancer: A tall order. Eur J Cancer. 2017 08; 81:226-227. PMID: 28629596; PMCID: PMC6051349.
      Citations:    Fields:    Translation:HumansCells
    65. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555. PMID: 28346412; PMCID: PMC5466900.
      Citations: 199     Fields:    Translation:HumansAnimalsCells
    66. Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Soghomonyan S, Alauddin MM, Flores LG, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Gelovani JG, Sidman RL, Pasqualini R, Arap W, Card?-Vila M, Arap MA, Marchi? S. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):12786-12791. PMID: 27791181; PMCID: PMC5111687.
      Citations: 21     Fields:    
    67. Maity SN, Titus MA, Gyftaki R, Wu G, Lu JF, Ramachandran S, Li-Ning-Tapia EM, Logothetis CJ, Araujo JC, Efstathiou E. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep. 2016 10 17; 6:35354. PMID: 27748439; PMCID: PMC5066251.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    68. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 2016 Jul 19; 7(29):46321-46334. PMID: 27331874; PMCID: PMC5216801.
      Citations: 9     Fields:    Translation:HumansAnimals
    69. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2019 12; 30(12):e3. PMID: 27141017.
      Citations: 10     Fields:    
    70. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93. PMID: 27322462; PMCID: PMC4909608.
      Citations: 2     Fields:    Translation:Humans
    71. Spiliotis J, Argiriou EO, Vafias E, Manou V, Vaos N, Datsis A, Efstathiou E. Re-admissions for delayed complications after cytoreductive surgery and HIPEC. Acta Chir Belg. 2016 Apr; 116(2):96-100. PMID: 27385296.
      Citations:    
    72. Efstathiou E, Soo Kim C, Horchani A, Hitier S, ?zen H, Droz JP, Yildirim A, Cabrera P, Heidenreich A, Rinck-Junior JA. First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry. Urol Oncol. 2016 May; 34(5):234.e21-9. PMID: 26777260.
      Citations: 4     Fields:    Translation:Humans
    73. Drivalos A, Chrisofos M, Efstathiou E, Kapranou A, Kollaitis G, Koutlis G, Antoniou N, Karanastasis D, Dimopoulos MA, Bamias A. Expression of a5-integrin, a7-integrin, ?-cadherin, and N-cadherin in localized prostate cancer. Urol Oncol. 2016 Apr; 34(4):165.e11-8. PMID: 26652134.
      Citations: 13     Fields:    Translation:Humans
    74. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):107-21. PMID: 26272062; PMCID: PMC4703437.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    75. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Nov; 68(5):850-8. PMID: 26153564.
      Citations: 26     Fields:    Translation:Humans
    76. Salameh A, Lee AK, Efstathiou E, Staquicini FI, Dobroff AS, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Calin GA, Cavenee WK, Pasqualini R, Arap W, Card?-Vila M, Nunes DN, Marchi? S, Lima LA, Carraro DM, Brentani RR, Dias-Neto E. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8403-8. PMID: 26080435; PMCID: PMC4500257.
      Citations: 99     Fields:    Translation:HumansAnimalsCells
    77. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Hussain M, James ND, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Heidenreich A, Lecouvet FE, Olmos D, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015 Aug; 26(8):1589-604. PMID: 26041764; PMCID: PMC4511225.
      Citations: 94     Fields:    Translation:Humans
    78. Pasqualini R, Millikan RE, Christianson DR, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W, Card?-Vila M. Targeting the interleukin-11 receptor a in metastatic prostate cancer: A first-in-man study. Cancer. 2015 Jul 15; 121(14):2411-21. PMID: 25832466; PMCID: PMC4490036.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    79. Goussetis E, Efstathiou E, Paisiou A, Avgerinou G, Zisaki K, Giamouris VJ, Peristeri I, Kitra V, Vessalas G, Gamaletsou MN, Sipsas NV, Graphakos S. Infectious complications following allogeneic stem cell transplantation by using anti-thymocyte globulin-based myeloablative conditioning regimens in children with hemoglobinopathies. Transpl Infect Dis. 2015 Apr; 17(2):201-7. PMID: 25645592.
      Citations: 4     Fields:    Translation:Humans
    80. Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R, ELM-PC 4 investigators, Saad F. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015 Mar; 16(3):338-48. PMID: 25701170.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    81. Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer. Eur Urol. 2015 Nov; 68(5):795-801. PMID: 25698064; PMCID: PMC5013546.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    82. Halkia E, Tsochrinis A, Vassiliadou DT, Pavlakou A, Vaxevanidou A, Datsis A, Efstathiou E, Spiliotis J. Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen HIPEC. Int J Surg Oncol. 2015; 2015:610597. PMID: 25785194; PMCID: PMC4345051.
      Citations: 11     Fields:    Translation:Humans
    83. Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015 Mar 01; 33(7):723-31. PMID: 25624429; PMCID: PMC4879718.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    84. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015 May; 22(5):1570-5. PMID: 25391263.
      Citations: 98     Fields:    Translation:HumansCTClinical Trials
    85. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 03; 6(252):252ra122. PMID: 25186177; PMCID: PMC4407499.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    86. Aapro M, Balducci L, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick JM, Heidenreich A, Hughes S, Joniau S, Kattan M, Mottet N, Payne H, Sugihara T, Droz JP, Boyle H, Oudard S, Saad F. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014 Aug; 15(9):e404-14. PMID: 25079103.
      Citations: 59     Fields:    Translation:Humans
    87. Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol. 2015 May; 67(5):866-73. PMID: 25018037.
      Citations: 18     Fields:    Translation:Humans
    88. Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Jonasch D, Zhang X, Conti CJ, Efstathiou E, Tannir NM, Eissa NT, Mills GB, Walker CL, Jonasch E. Autophagy mediates HIF2a degradation and suppresses renal tumorigenesis. Oncogene. 2015 May 07; 34(19):2450-60. PMID: 24998849; PMCID: PMC4286517.
      Citations: 41     Fields:    Translation:HumansCells
    89. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):53-60. PMID: 24882673; PMCID: PMC4247811.
      Citations: 96     Fields:    Translation:HumansCellsCTClinical Trials
    90. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014 May 20; 7(326):ra47. PMID: 24847116; PMCID: PMC4135429.
      Citations: 47     Fields:    Translation:HumansAnimals
    91. Wilton JH, Titus MA, Efstathiou E, Fetterly GJ, Mohler JL. Androgenic biomarker prof|ling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate. 2014 May; 74(7):722-31. PMID: 24847527; PMCID: PMC4335642.
      Citations: 9     Fields:    Translation:Humans
    92. Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Gillessen S, Kellokumpu-Lehtinen PL, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R, Tombal B, Foss? S, Lecouvet FE. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. Eur J Cancer. 2014 Jun; 50(9):1617-27. PMID: 24703899.
      Citations: 50     Fields:    Translation:Humans
    93. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Van Poppel H, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Fradet Y, Carles J, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25. PMID: 24647231; PMCID: PMC4418928.
      Citations: 86     Fields:    Translation:HumansCTClinical Trials
    94. Spiliotis JD, Halkia E, Boumis VA, Vassiliadou DT, Pagoulatou A, Efstathiou E. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Int J Surg Oncol. 2014; 2014:987475. PMID: 24809147; PMCID: PMC4009200.
      Citations: 12     Fields:    Translation:Humans
    95. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013 Dec 05; 155(6):1309-22. PMID: 24315100; PMCID: PMC3932525.
      Citations: 410     Fields:    Translation:HumansAnimalsCells
    96. Araujo JC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ, Trudel GC. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1307-16. PMID: 24211163; PMCID: PMC5478530.
      Citations: 94     Fields:    Translation:HumansCTClinical Trials
    97. Som A, Xiao L, Zhu R, Guo CC, Xiao L, Rao P, Efstathiou E, Matin A, Tu SM. Clinically atypical seminomas with yolk sac tumor features. Can J Urol. 2013 Aug; 20(4):6860-7. PMID: 23930614.
      Citations: 1     Fields:    Translation:Humans
    98. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013 Aug; 3(8):849-61. PMID: 23811619; PMCID: PMC3926428.
      Citations: 66     Fields:    Translation:Humans
    99. Mourmouris P, Efstathiou E, Papatsoris A. Androgen deprivation therapy and cardiovascular risk. Nephrourol Mon. 2013; 5(1):653-4. PMID: 23577326; PMCID: PMC3614327.
      Citations: 2     
    100. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48. PMID: 23228172; PMCID: PMC3683570.
      Citations: 869     Fields:    Translation:Humans
    101. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012 Dec; 13(12):1210-7. PMID: 23142059.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    102. Dimopoulos S, Eleftherakis E, Charitos C, Sakellaridis T, Sinapidis D, Kostis E, Toumanidis S, Efstathiou E. Bartonella quintana endocarditis as a cause of severe aortic insufficiency and heart failure. Hellenic J Cardiol. 2012 Nov-Dec; 53(6):476-9. PMID: 23178432.
      Citations:    Fields:    Translation:Humans
    103. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate. 2013 Jan; 73(2):153-61. PMID: 22753310; PMCID: PMC3878994.
      Citations: 12     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    104. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate. 2012 Nov; 72(15):1638-47. PMID: 22457212; PMCID: PMC4977841.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    105. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One. 2012; 7(2):e31259. PMID: 22363599; PMCID: PMC3281954.
      Citations: 4     Fields:    Translation:HumansCells
    106. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of ?-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res. 2012 Feb 01; 18(3):726-36. PMID: 22298898; PMCID: PMC3271798.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    107. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W, Koumakpayi IH. Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol. 2012 Mar; 180(3):895-903. PMID: 22245216; PMCID: PMC4715215.
      Citations: 37     Fields:    Translation:AnimalsCells
    108. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012 Feb 20; 30(6):637-43. PMID: 22184395; PMCID: PMC3295561.
      Citations: 80     Fields:    Translation:HumansCTClinical Trials
    109. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012 Feb 01; 18(3):666-77. PMID: 22156612; PMCID: PMC3923417.
      Citations: 70     Fields:    Translation:HumansAnimals
    110. Staquicini FI, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W, Card?-Vila M, Setubal JC. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18637-42. PMID: 22049339; PMCID: PMC3219136.
      Citations: 42     Fields:    Translation:HumansCells
    111. Logothetis CJ, Efstathiou E, Manuguid F, Kirkpatrick P. Abiraterone acetate. Nat Rev Drug Discov. 2011 Aug 01; 10(8):573-4. PMID: 21804589.
      Citations: 6     Fields:    Translation:Humans
    112. Spiliotis JD, Halkia EA, Efstathiou E. Peritoneal carcinomatosis 2011; it's about time for chemosurgery. J BUON. 2011 Jul-Sep; 16(3):400-8. PMID: 22006740.
      Citations: 5     Fields:    Translation:Humans
    113. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61. PMID: 21632851; PMCID: PMC3657705.
      Citations: 93     Fields:    Translation:HumansCTClinical Trials
    114. Tzelepi V, Karlou M, Wen S, Hoang A, Logothetis C, Troncoso P, Efstathiou E. Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology. 2011 Jun; 58(7):1037-47. PMID: 21707705; PMCID: PMC4934422.
      Citations: 24     Fields:    Translation:Humans
    115. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators, Fl?chon A. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26; 364(21):1995-2005. PMID: 21612468; PMCID: PMC3471149.
      Citations: 1619     Fields:    Translation:HumansCTClinical Trials
    116. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20; 29(18):2574-81. PMID: 21606419; PMCID: PMC3138635.
      Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
    117. Drivalos A, Papatsoris AG, Chrisofos M, Efstathiou E, Dimopoulos MA. The role of the cell adhesion molecules (integrins/cadherins) in prostate cancer. Int Braz J Urol. 2011 May-Jun; 37(3):302-6. PMID: 21756376.
      Citations: 5     Fields:    Translation:Humans
    118. Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Bamias A, Dimopoulos MA. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res. 2011 Apr; 31(4):1475-82. PMID: 21508406.
      Citations: 9     Fields:    Translation:Humans
    119. Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A, Dimopoulos MA. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology. 2011 Mar; 77(3):682-7. PMID: 21256546.
      Citations: 10     Fields:    Translation:Humans
    120. Eleutherakis-Papaiakovou E, Kostis E, Migkou M, Christoulas D, Terpos E, Gavriatopoulou M, Roussou M, Bournakis E, Kastritis E, Efstathiou E, Dimopoulos MA, Papadimitriou CA. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol. 2010 Nov; 85(11):863-7. PMID: 20882526.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    121. Bourdoumis A, Papatsoris AG, Chrisofos M, Efstathiou E, Skolarikos A, Deliveliotis C. The novel prostate cancer antigen 3 (PCA3) biomarker. Int Braz J Urol. 2010 Nov-Dec; 36(6):665-8; discussion 669. PMID: 21176272.
      Citations: 6     Fields:    Translation:Humans
    122. Som A, Zhu R, Guo CC, Efstathiou E, Xiao L, Pisters LL, Matin A, Tu SM. Recurrent seminomas: clinical features and biologic implications. Urol Oncol. 2012 Jul-Aug; 30(4):494-501. PMID: 20822932; PMCID: PMC3856193.
      Citations: 4     Fields:    Translation:Humans
    123. Karlou M, Tzelepi V, Efstathiou E. Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol. 2010 Sep; 7(9):494-509. PMID: 20818327.
      Citations: 54     Fields:    Translation:HumansCells
    124. Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010 Oct; 24(10):1769-78. PMID: 20739955.
      Citations: 47     Fields:    Translation:HumansCells
    125. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24; 375(9724):1437-46. PMID: 20398925; PMCID: PMC2948179.
      Citations: 445     Fields:    Translation:HumansCTClinical Trials
    126. Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010 Jul; 85(1):1-5. PMID: 20192988.
      Citations: 19     Fields:    Translation:Humans
    127. Efstathiou E, Logothetis CJ. A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res. 2010 Feb 15; 16(4):1100-7. PMID: 20145177; PMCID: PMC3891669.
      Citations: 17     Fields:    Translation:Humans
    128. Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol. 2010 Jun; 57(6):1030-8. PMID: 19853370; PMCID: PMC2962710.
      Citations: 20     Fields:    Translation:Humans
    129. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation: a demanding taskmaster. J Clin Oncol. 2009 Oct 20; 27(30):4937-8. PMID: 19720892.
      Citations: 1     Fields:    Translation:Humans
    130. Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efstathiou E, Logothetis CJ. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics. 2009 Aug 04; 2:48. PMID: 19653896; PMCID: PMC2731785.
      Citations: 26     Fields:    
    131. Efstathiou E, Logothetis CJ. Prostate cancer: thalidomide for prostate cancer: is there progress? Nat Rev Urol. 2009 May; 6(5):248-50. PMID: 19424170.
      Citations:    Fields:    Translation:Humans
    132. Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther. 2009 Apr; 9(4):465-79. PMID: 19344283.
      Citations: 9     Fields:    Translation:HumansAnimals
    133. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20. PMID: 19244175; PMCID: PMC2734116.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    134. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther. 2008 Oct; 7(10):1619-27. PMID: 19018165.
      Citations: 7     Fields:    Translation:Humans
    135. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710. PMID: 18618013; PMCID: PMC2447924.
      Citations: 105     Fields:    Translation:HumansAnimalsCells
    136. Papadimitriou C, Dafni U, Anagnostopoulos A, Vlachos G, Voulgaris Z, Rodolakis A, Aravantinos G, Bamias A, Bozas G, Kiosses E, Gourgoulis GM, Efstathiou E, Dimopoulos MA. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. Bone Marrow Transplant. 2008 Mar; 41(6):547-54. PMID: 18026149.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    137. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL, McDonnell TJ, Logothetis CJ. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1224-31. PMID: 17317833.
      Citations: 24     Fields:    Translation:HumansCellsCTClinical Trials
    138. Efstathiou E, Dimopoulos MA, Bozas G, Kastritis E, Moulopoulos LA, Rodolakis A, Vlahos G, Gika D, Papadimitriou C, Bamias A. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res. 2007 Jan-Feb; 27(1B):611-7. PMID: 17348450.
      Citations: 4     Fields:    Translation:HumansCells
    139. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw. 2006 Nov; 4(10):1059-70. PMID: 17112453.
      Citations: 12     Fields:    Translation:HumansPHPublic Health
    140. Bozas G, Bamias A, Koutsoukou V, Efstathiou E, Gika D, Papadimitriou CA, Dimopoulos MA. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol. 2007 Mar; 104(3):580-5. PMID: 17052747.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    141. Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, Dimopoulos MA. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer. 2006 Sep 25; 6:228. PMID: 16999858; PMCID: PMC1592509.
      Citations: 1     Fields:    Translation:Humans
    142. Bozas G, Dimopoulos MA, Kastritis E, Efstathiou E, Koutsoukou V, Rodolakis A, Vlahos G, Voulgaris Z, Papageorgiou T, Gika D, Papadimitriou C, Bamias A. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology. 2006; 70(4):265-72. PMID: 16899981.
      Citations: 5     Fields:    Translation:Humans
    143. Mauri D, Pentheroudakis G, Bafaloukos D, Pectasides D, Samantas E, Efstathiou E, Kalofonos HP, Syrigos K, Klouvas G, Papakostas P, Kosmidis P, Fountzilas G, Pavlidis N, Hellenic Coopeprative Oncologic Group (HeCOG). Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res. 2006 Jul-Aug; 26(4B):3175-81. PMID: 16886653.
      Citations: 18     Fields:    Translation:Humans
    144. Kastritis E, Efstathiou E, Gika D, Bozas G, Koutsoukou V, Papadimitriou C, Pissakas G, Dimopoulos MA, Bamias A. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. Int J Gynecol Cancer. 2006 May-Jun; 16(3):994-9. PMID: 16803475.
      Citations: 10     Fields:    Translation:Humans
    145. Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res. 2005 Dec 01; 11(23):8384-90. PMID: 16322299.
      Citations: 12     Fields:    Translation:HumansCells
    146. Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res. 2005 Sep-Oct; 25(5):3553-8. PMID: 16101179.
      Citations: 21     Fields:    Translation:Humans
    147. Kastritis E, Bamias A, Efstathiou E, Gika D, Bozas G, Zorzou P, Sarris K, Papadimitriou C, Dimopoulos MA. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. Gynecol Oncol. 2005 Nov; 99(2):376-82. PMID: 16051322.
      Citations: 16     Fields:    Translation:Humans
    148. Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, Dimopoulos MA. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer. 2005 Jun 15; 103(12):2629-35. PMID: 15856427.
      Citations: 12     Fields:    Translation:Humans
    149. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005 May; 97(2):436-41. PMID: 15863142.
      Citations: 36     Fields:    Translation:Humans
    150. Bafaloukos D, Tsoutsos D, Kalofonos H, Chalkidou S, Panagiotou P, Linardou E, Briassoulis E, Efstathiou E, Polyzos A, Fountzilas G, Christodoulou C, Kouroussis C, Iconomou T, Gogas H. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol. 2005 Jun; 16(6):950-7. PMID: 15829494.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    151. Xiros N, Papacostas P, Economopoulos T, Samelis G, Efstathiou E, Kastritis E, Kalofonos H, Onyenadum A, Skarlos D, Bamias A, Gogas H, Bafaloukos D, Samantas E, Kosmidis P. Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005 May; 16(5):773-9. PMID: 15802284.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    152. Bamias A, Efstathiou E, Moulopoulos LA, Gika D, Hamilos G, Zorzou MP, Kakoyiannis C, Kastritis E, Bozas G, Papadimitriou C, Dimopoulos MA. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol. 2005 Feb; 16(2):307-13. PMID: 15668289.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    153. Zorzou MP, Efstathiou E, Galani E, Bozas G, Kastritis E, Papadimitriou C, Dimopoulos MA, Bamias A. Carboplatin hypersensitivity reactions: a single institution experience. J Chemother. 2005 Feb; 17(1):104-10. PMID: 15828452.
      Citations: 2     Fields:    Translation:Humans
    154. Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. Urology. 2005 Jan; 65(1):126-30. PMID: 15667877.
      Citations: 8     Fields:    Translation:Humans
    155. Bamias A, Efstathiou E, Vassilakopoulou M, Koutsoukou V, Papadimitriou C, Rodolakis A, Mitsibounas D, Vlahos G, Dimopoulos MA. Late relapse of epithelial ovarian cancer: a single institution experience. Eur J Gynaecol Oncol. 2005; 26(4):439-42. PMID: 16122198.
      Citations: 1     Fields:    Translation:Humans
    156. Dimopoulos MA, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol. 2004 Dec; 95(3):695-700. PMID: 15581984.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    157. Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C, Bafaloukos D, Athanasios Dimopoulos M, Bamias A, Phase II study of Hellenic Co-operative Oncology Group. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004 Sep; 64(3):479-84. PMID: 15351574.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    158. Dimopoulou I, Efstathiou E, Samakovli A, Dafni U, Moulopoulos LA, Papadimitriou C, Lyberopoulos P, Kastritis E, Roussos C, Dimopoulos MA. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. Ann Oncol. 2004 Aug; 15(8):1250-5. PMID: 15277266.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    159. Zorzou MP, Stratigos A, Efstathiou E, Bamias A. Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm Venereol. 2004; 84(4):308-9. PMID: 15339078.
      Citations: 11     Fields:    Translation:Humans
    160. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, Poziopoulos C, Xilouri I, Zorzou MP, Anagnostopoulos N, Anagnostopoulos A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004; 5(2):112-7. PMID: 15048060.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    161. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, Hamilos G, Zorzou M, Dimopoulos MA. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 2004; 66(2):112-7. PMID: 15138362.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    162. Dimopoulos MA, Hamilos G, Efstathiou E, Siapkaras I, Matsouka C, Gika D, Grigoraki V, Papadimitriou C, Mitsibounas D, Anagnostopoulos N. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma. 2003 Jun; 44(6):993-6. PMID: 12854900.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    163. Kroupis C, Lianidou E, Goutas N, Ladopoulou A, Konstantopoulou I, Pantazidis A, Yannoukakos D, Efstathiou E, Vourlidis N, Tsionou C. Atypical medullary breast carcinoma in a family carrying the 5382insC BRCA-1 mutation. Breast J. 2003 May-Jun; 9(3):260-2. PMID: 12752644.
      Citations: 2     Fields:    Translation:Humans
    164. Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopoulos N, Christakis J. Extended rituximab therapy for previously untreated patients with Waldenstr?m's macroglobulinemia. Clin Lymphoma. 2002 Dec; 3(3):163-6. PMID: 12521393.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    165. Ladopoulou A, Kroupis C, Konstantopoulou I, Ioannidou-Mouzaka L, Schofield AC, Pantazidis A, Armaou S, Tsiagas I, Lianidou E, Efstathiou E, Tsionou C, Panopoulos C, Mihalatos M, Nasioulas G, Skarlos D, Haites NE, Fountzilas G, Pandis N, Yannoukakos D. Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Lett. 2002 Nov 08; 185(1):61-70. PMID: 12142080.
      Citations: 13     Fields:    Translation:Humans
    166. Dimopoulos MA, Papadimitriou CA, Sarris K, Aravantinos G, Kalofonos C, Gika D, Gourgoulis GM, Efstathiou E, Skarlos D, Bafaloukos D. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. Gynecol Oncol. 2002 Jun; 85(3):476-82. PMID: 12051877.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    167. Ladopoulou A, Konstantopoulou I, Armaou S, Efstathiou E, Mihalatos M, Nasioulas G, Bardi G, Pandis N, Yannoukakos D, Hellenic Cooperative Oncology Group. A change in the last base of BRCA1 exon 23, 5586G-->A, results in abnormal RNA splicing. Cancer Genet Cytogenet. 2002 Apr 15; 134(2):175-7. PMID: 12034536.
      Citations: 1     Fields:    Translation:HumansCells
    168. Christodoulou C, Klouvas G, Efstathiou E, Zervakis D, Papazachariou E, Plyta M, Skarlos DV. Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology. 2002; 62(2):97-102. PMID: 11914593.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    169. Konstantopoulou I, Kroupis C, Ladopoulou A, Pantazidis A, Boumba D, Lianidou ES, Petersen MB, Florentin L, Chiotellis E, Nounesis G, Efstathiou E, Skarlos D, Tsionou C, Fountzilas G, Yannoukakos D. BRCA1 mutation analysis in breast/ovarian cancer families from Greece. Hum Mutat. 2000 Sep; 16(3):272-3. PMID: 10980541.
      Citations: 7     Fields:    Translation:Humans
    170. Janinis J, Efstathiou E, Panopoulos C, Samantas E, Aravantinos G, Christodoulou C, Skarlos D. Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status. Med Oncol. 2000 May; 17(2):106-10. PMID: 10871815.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    171. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). European Urology. 66:815-825.
    172. First-line treatment in senior adults with metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations.
    173. Integrating murine and clinical trials with cabozantinib to understand roles of MET and VEGFR2 as targets for growth inhibition of prostate cancer. Clinical Cancer Research. 22:107-121.
    174. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Scientific Reports. 6.
    175. Targeted molecular-genetic imaging and liganddirected therapy in aggressive variant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 113:12786-12791.
    176. Clinical trials in oncology. Forum of Clinical Oncology. 3:9-13.
    177. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 7:46321-46334.
    178. Erratum. Science Translational Medicine. 7.
    179. Management of patients with advanced prostate cancer. Annals of Oncology. 26:1589-1604.
    180. Clinical Challenges for Treatment and a Cure. 155-167.
    181. Urologic Oncology: Seminars and Original Investigations. 34:165.e11-165.e18.
    182. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine.
    183. Clinically atypical seminomas with yolk sac tumor features. Canadian Journal of Urology. 20:6860-6867.
    EFSTATHIOU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (596)
    Explore
    _
    Co-Authors (97)
    Explore
    _
    Similar People (59)
    Explore
    _
    Same Department Expand Description
    Explore
    _